Yuhua Jiang

Yuhua Jiang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FSFawad Ali Shah
Fawad Ali Shah
LKLina Al Kury
Lina Al Kury
TLTao Li
Tao Li
AZAlam Zeb
Alam Zeb
PKPhil Ok Koh
Phil Ok Koh
SLShupeng Li
Shupeng Li
Ischemic stroke is characterized by permanent or transient obstruction of blood flow, which initiates a cascading pathological process, starting from acute ATP loss and ionic imbalance to subsequent membrane depolarization, glutamate excitotoxicity, and calcium overload. These initial events are followed by neuroinflammation and oxidative stress, eventually causing neuronal neurosis and apoptosis. Complicated interplays exist between these steps happening across various stages, which not only represent the complicated nature of ischemic pathology but also warrant a detailed delineation of the underlying molecular mechanisms to develop better therapeutic options. In the present study, we examined the neuroprotective effects of polydatin against ischemic brain injury using a rat model of permanent middle cerebral artery occlusion (MCAO). Our results demonstrated that polydatin treatment reduced the infarction volume and mitigated the neurobehavioral deficits, sequentially rescued neuronal apoptosis. Ischemic stroke induced an elevation of neuroinflammation and reactive oxygen species, which could be attenuated by polydatin via the reduced activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase. In addition, polydatin upregulated the endogenous antioxidant nuclear factor erythroid 2-related factor 2, heme oxygenase-1, the thioredoxin pathway, and eventually reversed ischemic-stroke-induced elevation of ROS and inflammation in ischemic cortical tissue. The diverse and broad actions of polydatin suggested that it could be a multiple targeting neuroprotective agent in ameliorating the detrimental effects of MCAO, such as neuroinflammation, oxidative stress, and neuronal apoptosis. As repetitive clinical trials of neuroprotectants targeting a single step of stroke pathological process have failed previously, our results suggested that a neuroprotective strategy of acting at different stages may be more advantageous to intervene in the vicious cycles in MCAO.

29 March 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FSFawad Ali Shah
Fawad Ali Shah
GLGongping Liu
Gongping Liu
LKLina T. Al Kury
Lina T. Al Kury
AZAlam Zeb
Alam Zeb
PKPhil-Ok Koh
Phil-Ok Koh
SLShupeng Li
Shupeng Li
Stroke is the significant cause of human mortality and sufferings depending upon race and demographic location. Melatonin is a potent antioxidant that exerts protective effects in differential experimental stroke models. Several mechanisms have been previously suggested for the neuroprotective effects of melatonin in ischemic brain injury. The aim of this study is to investigate whether melatonin treatment affects the glutamate N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor signaling in cerebral cortex and striatum 24 h after permanent middle cerebral artery occlusion (MCAO). Melatonin (5 mg/kg) attenuated ischemia-induced down regulation of NMDA receptor 2 (NR2a), postsynaptic density-95 (PSD95) and increases NR2a/PSD95 complex association, which further activates the pro-survival PI3K/Akt/GSK3β pathway with mitigated collapsin response mediator protein 2 (CRMP2) phosphorylation. Furthermore, melatonin increases the expression of γ-enolase, a neurotrophic factor in ischemic cortex and striatum, and preserve the expression of presynaptic (synaptophysin and SNAP25) and postsynaptic (p-GluR1845) protein. Our study demonstrated a novel neuroprotective mechanism for melatonin in ischemic brain injury which could be a promising neuroprotective agent for the treatment of ischemic stroke.

7 November 2013 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YZYong Zhou
Yong Zhou
YXYing Xu
Ying Xu
HWHan Wang
Han Wang
JNJunjie Niu
Junjie Niu
HHHuaying Hou
Huaying Hou
YJYuhua Jiang
Yuhua Jiang
Valproic acid (VPA) is a well‑tolerated drug that is used to treat seizure disorders and that has recently been shown to inhibit histone deacetylase. The present study investigated the effects of VPA on the radiosensitization of the rat C6 glioma cell line in vitro. To select an appropriate treatment concentration and time, MTT and flow cytometry assays were performed to measure the inhibitory effects of VPA at various concentrations and incubation time‑points. The radiosensitizing effect of VPA was determined using clonogenic experiments. VPA‑ and radiation‑induced C6 apoptosis was analyzed using quantitative polymerase chain reaction and western blot analysis. Cell proliferation was significantly inhibited by VPA in a time‑ and dose‑dependent manner (P<0.05). VPA enhanced radiation‑induced C6 cell death and there was clear inhibition of clonogenic formation [sensitizer enhancement ratio (SER), 1.30]. This effect was closely associated with the concentration of VPA. VPA treatment decreased the mRNA and protein levels of Bcl‑2, whereas increased changes were detected with Bax. At a concentration of 0.5 mmol/l, VPA had a low toxicity and enhanced the radiosensitization of the C6 cells. VPA may radiosensitize glioma cells by inhibiting cellular proliferation and inducing apoptosis by regulating apoptosis‑related molecular changes.

16 August 2021 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
SRShafiq Ur Rahman
Shafiq Ur Rahman
TATahir Ali
Tahir Ali
QHQiang Hao
Qiang Hao
KHKaiwu He
Kaiwu He
WLWeifen Li
Weifen Li
SLShupeng Li
Shupeng Li

22 April 2019 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
HHHuaying Hou
Huaying Hou
XYXiaoming Yu
Xiaoming Yu
PCPing Cong
Ping Cong
YZYong Zhou
Yong Zhou
YXYing Xu
Ying Xu
YJYuhua Jiang
Yuhua Jiang
Objectives: The roles and related mechanisms of six2 in regulating non–small cell lung cancer (NSCLC) cells progression are unclear. This work aimed to explore the roles of six2 in NSCLC cell stemness.Materials and Methods: Kaplan‐Meier plotter analysis was used to examine the correlation between six2 expression and the survival of NSCLC patients. Quantitative reverse transcription PCR and Western blot were performed to detect six2 expression in clinical samples. Moreover, transwell migration, tumour spheroid formation and in vivo tumour formation assays were used to examine the effects of six2 on NSCLC cell progression. Additionally, methylation analysis was carried out to measure E‐cadherin methylation level in different cells. Finally, cell viability assay was performed to explore the effects of six2 on chemotherapeutic sensitivity of NSCLC cells.Results: Lung cancer patients with a higher six2 expression level displayed a shorter overall survival. Six2 expression was higher in lung cancer tissues than in normal adjacent tissues. Additionally, six2 knockdown suppressed NSCLC cell stemness. Mechanistically, six2 overexpression inhibited epithelial marker E‐cadherin expression via stimulating its promoter methylation. And E‐cadherin knockdown rescued six2 knockdown‐induced decrease of NSCLC cancer cell stemness. Notably, six2 knockdown enhanced cisplatin sensitivity in parental NSCLC cells and attenuated cisplatin resistance in cisplatin‐resistant NSCLC cells.Conclusions: Our results suggest that six2 facilitates NSCLC cell stemness and attenuates chemotherapeutic sensitivity via suppressing E‐cadherin expression.

1 October 2014 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
YZYong Zhou
Yong Zhou
JNJunjie Niu
Junjie Niu
SLShupeng Li
Shupeng Li
HHHuaying Hou
Huaying Hou
YXYing Xu
Ying Xu
YJYuhua Jiang
Yuhua Jiang
Radiotherapy is commonly used in the treatment of brain tumors but can cause significant damage to surrounding normal brain. The radioprotective effects of valproic acid (VPA) on normal tissue in the rat brain were evaluated following irradiation. Male Wistar rats were used in the present study and 48 rats were randomly divided into four groups consisting of 12 rats each. The whole‑brain irradiation (WBI) was delivered by X‑ray and the rats received the following treatment once a day for 5 days. The control group (sham‑exposed group) received sham irradiation plus physiological saline. The VPA group received sham irradiation plus 150 mg VPA/kg. The X‑ray group received WBI plus physiological saline. The combined group received WBI plus 150 mg/kg intraperitoneally VPA. A total of 6 months post‑irradiation, the rats were sacrificed and the brains were harvested. Cell apoptosis in the cortex was determined by immunohistochemistry 24 h post‑irradiation using an antibody for protein caspase‑3. Transmission electron microscope (TEM) analyses were used to assess the effects of VPA on the radioprotection of rat normal brain cells 6 months post‑irradiation. The weights of the animals in the TEM group measured over the two weeks after the first injection of VPA were also observed. Histological findings demonstrated that apoptosis occurred on the cortex 1 day after treatment, peaking in the X‑ray group. The cells of the combined group showed a moderate caspase‑3 staining compared to the X‑ray group. There was a trend towards a lower body weight of the X‑ray group following irradiation compared to either no‑irradiation or rats of the combined group, although there was no significant difference in the average weight between the combined group and irradiated rats. Mild swelling of the capillary endothelial cells in the irregular lumen was observed in the combined group, whereas the X‑ray group showed a severe structural disorder. In conclusion, VPA supplementation during radiotherapy may be beneficial for radioprotection following WBI by reducing normal brain cell injury.